Citations

Clear

3042 citation(s) found for "Kumar, S".

Treatment Approaches for Obesity in Children With Heterozygous MC4R Variants
Salama, Mostafa , Saba, Leslie , Valdez, Lourdes, Lteif, Aida, Kumar, Seema, Saba, Leslie , Salama, Mostafa , Valdez, Lourdes

Mayo Clinic

Clinical Obesity | January 5, 2026 | Volume: 16 | Issue: 1 | Pages: No page available

10.1111/cob.70069 | PMID 41489233 Get It

ABSTRACT Melanocortin‐4 receptor (MC4R) deficiency is the most common cause of monogenic obesity; yet treatment options for children with MC4R mutations are limited. We describe significant improvement in weight in three patients with pathogenic or likely pathogenic MC4R mutations; two adolescents treated with semaglutide, and a younger child treated with metformin and topiramate. These findings indicate GLP‐1 receptor agonists, topiramate and metformin can be helpful in managing obesity associated with MC4R deficiency.
Efficacy and Safety of Sotatercept in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
Ashraf, Saad, Magsi, Iffat Ambreen, Kumar, Sumet , Kumar, Dinesh , Kumar, Sumeet, Chandar, Subhash, Kumar, Laksh , Rao, Hammad, Ashraf, Saad , Magsi, Iffat Ambreen , Kumar, Dinesh , Kumar, Laksh , Kumar, Mukesh , Raja, Adarsh

Mayo Clinic

American Journal of Therapeutics | January 5, 2026 | Volume: 33 | Issue: 2 | Pages: e172-e175

10.1097/mjt.0000000000002099 | PMID 41486471 Get It

Comparison of FRACTURE MRI, Conventional Radiography, and CT in the Evaluation of Bone Tumors
Janu, Amit , Rai, Pranjal , Choudhari, Amit Jayant, Gala, Kunal , Pruthi, Manish , Ramadwar, Mukta, Panjwani, P., Pathak, Pankhudi, Parambil, Badira Cheriyankil, Khanna, N., Laskar, S., Janu, Amit Kumar , Shetty, Nitin , Rai, Pranjal , Choudhari, Amit J., Puri, Ajay , Ramadwar, Mukta R. , Panjwani, Poonam K. , Nayak, Prakash, Chakrabarty, Nivedita , Parambil, Badira Cheriyalinkal , Kulkarni, Suyash Sureshchandra

Mayo Clinic

Radiology: Imaging Cancer | January 2, 2026 | Volume: 8 | Issue: 1 | Pages: No page available

10.1148/rycan.240525 | PMID 41481491 Get It

FRACTURE MRI demonstrated strong agreement with conventional radiography and CT in evaluating key bone tumor characteristics, including lesion type, location, and matrix content.
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)( CCND1 ; IGH )
Wiedmeier-Nutor, Julia Erin, Jelinek, Tomas, Shivaram, Suganti, Tang, Hongwei , Owens, Rebecca W, Tereza, Ševčíková, Fonseca, Rodrigo , Zhao, Logan, Zhu, Yuan Xiao, Matulis, Shannon M. , Mitsiades, C., Hajek, R, Chesi, M., Bergsagel, P. Leif, Esteban, Braggio, Kumar, Shaji , Wiedmeier, Julia E. , Wiedmeier-Nutor, J Erin, Fonseca, Rodrigo , Durante, Michael , Diamond, Benjamin T , Zhu, Yuan X , Landgren, C Ola , Chesi, Marta , Bergsagel, P. Leif , Braggio, Esteban , Boise, Lawrence H , Fonseca, Rafael , Kumar, Shaji K , Maura, Francesco , Wiedmeier-Nutor, Julia E , Kaddoura, Marcella , Gupta, Vikas A. , Ziccheddu, Bachisio , Shivaram, Suganti, Sevcikova, Tereza, Durante, Michael , Diamond, Benjamin , Shi, Chang-Xin , Mitsiades, Constantine S. , Landgren, Ola , Usmani, Saad Z. , Hájek, Roman , Chesi, Marta , Bergsagel, P. Leif , Braggio, Esteban , Boise, Lawrence , Fonseca, Rafaël , Maura, Francesco , Baughn, Linda B.

Mayo Clinic

Blood | January 2, 2026 | Volume: 147 | Issue: 14 | Pages: 1598-1610

10.1182/blood.2025029996 | PMID 41481388 Get It

Abstract Multiple myeloma (MM) with t(11;14)(CCND1;IGH) remains the only subset sensitive to the BCL2 inhibitor venetoclax. However, not all patients with t(11;14)(CCND1;IGH) respond to treatment, and some progress early after initial response. To investigate this, we examined 44 whole-genome and whole-exome sequencing data samples from 34 patients with t(11;14) MM treated with venetoclax. The presence of mutations in the RAS pathway was strongly associated with shortened progression-free survival (PFS) and was validated in an independent cohort of 21 patients with MM. The presence of 1q gain was also associated with shorter PFS in patients without RAS mutations. In 10 patients with paired prevenetoclax and postvenetoclax treatment samples, postvenetoclax progression was recurrently driven by the selection of genomic events in the BCL2/MCL1 and RAS pathways and of high-risk features (eg, loss of TP53 and CDKN2C). Overall, our study shows that comprehensive genomic profiling can identify most mechanisms underlying resistance to BCL2 inhibition in t(11;14)(CCND1;IGH) MM.
Extramedullary Disease—Achilles Heel in Myeloma?
Kumar, Shaji, Richter, Joshua , Cohen, Yaël C. , Ye, J. Christine , Mateos, María‐Victoria, Hungria, Vania, Zamagni, Elena, Hungria, Vânia , Zamagni, Elena , Kumar, Shaji K , Cohen, Yael C , Hungria, Vania , Richter, Joshua , Zamagni, Elena , Kumar, Shaji , Usmani, Saad Z. , Mateos, María‐Victoria

Mayo Clinic

American Journal of Hematology | December 30, 2025 | Volume: 101 | Issue: 3 | Pages: 521-536

10.1002/ajh.70138 | PMID 41462032 Get It

ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion molecules, heterogeneous genetic and epigenetic changes, and a solid tumor‐like architecture within the microenvironment. Although the introduction of advanced imaging techniques and immunotherapy has led to improved detection and more promising outcomes and regimens, respectively, more prospective studies dedicated to true EMD are needed.
Quantitative Analysis of Nasal Septal Perforations Associated with Saddle Nose Deformity
Kumar, Nitish , Pace, Tyson, Gomes, Pedro Lança , Bansberg, Stephen F. , Marino, Michael J. , Lal, Devyani, Miglani, Amar , Kumar, Nitish

Mayo Clinic

Facial Plastic Surgery & Aesthetic Medicine | December 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/26893614251408035 | PMID 41460701 Get It

Achieving Alignment and Implant-Specific Goals in Anterior Lumbar Interbody Fusion, and Predictors of Postoperative Intradiscal Lordosis: The Role of Spinopelvic Parameters, Cage Lordosis, Intraoperative Consistency, Surgical Technique, and Treated Level
Hamouda, Abdelrahman, Pennington, Zach, Kumar, Rahul , Martini, Michael L. , Obiri-Yeboah, Derrick , Potes, Maria Astudillo, Kendall, Nicholas , Hafz, Omar , Clarke, Michelle J. , Krauss, William E. , Freedman, Brett A., Helgeson, Melvin D. , Sebastian, Arjun S. , Mikula, Anthony L., Fogelson, Jeremy L. , Elder, Benjamin D. , Pennington, Zach , Hamouda, Abdelrahman M. , Hamouda, Abdelrahman , Martini, Michael , Astudillo Potes, Maria , Helgeson, Melvin D , Sebastian, Arjun S , Mikula, Anthony L , Fogelson, Jeremy L , Elder, Benjamin D , Pennington, Zach , Clarke, Michelle J , Kumar, Rahul , Potes, Maria Astudillo , Hafz, Omar , Nassr, Ahmad , Freedman, Brett Arthur , Mikula, Anthony L.

Mayo Clinic

Operative Neurosurgery | December 29, 2025 | Volume: 31 | Issue: 3 | Pages: 431-444

10.1227/ons.0000000000001868 | PMID 41460067 Get It

BACKGROUND AND OBJECTIVES: Anterior lumbar interbody fusion (ALIF) is a powerful procedure for sagittal correction and indirect decompression in the lumbar spine, though aggressive correction can cause stretch neuropraxia and implant subsidence. The aim of this study was to identify radiographic and clinical predictors of segmental correction, as well as to evaluate the degree to which segmental correction on supine intraoperative radiographs translates to postoperative upright alignment changes. METHODS: We identified patients treated with 1- or 2-level ALIF at a tertiary care center and extracted data on demographics, spinopelvic parameters, and surgical details. Patients treated with isolated ALIF and ALIF with supplementary posterior instrumentation were compared on pre- and postoperative intradiscal lordosis (IDL) and change in IDL. Multivariable linear regression was performed to identify independent predictors of postoperative IDL. RESULTS: We included 204 patients (median age 57 years, 55.4% male) treated at 258 levels, of whom 114 (55.9%) underwent supplementary posterior fixation and 150 (73.5%) underwent single-level implantation. Across all patients, postoperative IDL was significantly greater than preoperative segmental lordosis (25.4° vs 15.3°; P < .001). Standalone ALIF achieved less ΔIDL than circumferential fusion for L5/S1 procedures (7.4° vs 11.6°; P < .001), though ΔIDL for L3/4 and L4/5 was similar between the standalone and circumferential groups. Multivariable analysis showed postoperative IDL to be predicted by greater preoperative IDL (β = 0.26° per degree; [0.15, 0.36]; P < .001), L5/S1 [vs L4/5] implantation (β = 3.97°; [2.72, 5.21]; P < .001), use of supplementary posterior fixation (β = 1.80°; [0.70, 2.89]; P < .001), and greater implant lordosis (β = 0.62° per degree; [0.44, 0.79]; P < .001). CONCLUSION: Postoperative IDL after 1- or 2-level ALIF is best predicted by placement of larger interbody sizes, L5/S1 implantation, greater baseline IDL, and use of adjunct posterior fixation. Patients with higher preoperative lordosis experienced smaller postoperative increases in IDL, though this was likely influenced by a treatment bias.
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era
Bazarbachi, Abdul‐Hamid , Zanwar, Saurabh , Trajanova, Despina, Gertz, Morie A., Dispenzieri, Angela, Kumar, Shaji, D'Souza, A, Patwari, Anannya , Cowan, Andrew, Chen, GuiZhen, Milani, P. , Palladini, Giovanni, Bodanapu, Geethika , Mohty, M, Lentzsch, Suzanne , Muchtar, E., Bazarbachi, Abdul Hamid , Chakraborty, Rajshekhar , Hegenbart, Ute , Bhutani, Divaya , Gertz, Morie A. , Dispenzieri, Angela , D’Souza, Anita , Milani, Paolo, Sanchorawala, Vaishali , Mohty, Mohamad , Schönland, Stefan , Muchtar, Eli , Chakraborty, Rajshekhar

Mayo Clinic

HemaSphere | December 29, 2025 | Volume: 9 | Issue: 12 | Pages: No page available

10.1002/hem3.70276 | PMID 41473002 Get It

Abstract Rapid and profound reduction of free light chains (FLCs) improves outcomes in AL amyloidosis; however, early FLC kinetics with daratumumab‐based frontline therapy remain undefined. We retrospectively analyzed 315 patients treated with daratumumab–bortezomib–cyclophosphamide–dexamethasone (Dara–VCd) or Dara–Vd at eight centers. Involved FLC (iFLC), the difference between iFLC and uninvolved FLC (dFLC), and hematologic response (≥very good partial response [VGPR]) were assessed at baseline and at 1, 3, and 6 months, and correlated with light chain isotype, disease burden (bone‐marrow plasma‐cell percentage [%BMPC], baseline dFLC), and cytogenetics. Hematological ≥VGPR increased from 49.8% at 1 month to 66.0% at 3 months. The kappa isotype showed slower responses, with higher iFLC/dFLC and lower ≥VGPR at each time point compared to lambda. Higher %BMPC or baseline dFLC predicted persistently elevated iFLC/dFLC and reduced ≥VGPR. The t(11;14) translocation was associated with lower baseline FLC but similar subsequent kinetics. BMPC < 10% and dFLC < 18 mg/dL independently predicted early ≥VGPR (in ≤1 month). Early ≥VGPR conferred superior hematologic event‐free survival (heme‐EFS) and overall survival (OS) versus later responders (P < 0.001). At a 3‐month landmark, achieving dFLC < 1 mg/dL further stratified prognosis, conferring longer heme‐EFS and OS (P < 0.01). Frontline Dara‐based therapy elicits rapid, deep responses in AL amyloidosis; early ≥VGPR (within 1 month) and dFLC < 1 mg/dL by 3 months predict durable EFS and OS, whereas higher baseline disease burden delays hematologic response.
Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia
Gibbons, Christopher H. , Levine, Todd, Bellaire, Bailey, Wang, Ningshan , Agarwal, Pinky , Aldridge, Georgina M. , Barboi, Alexandru, Claassen, Daniel O., Evidente, Virgilio G. H., Galasko, Douglas R., Gonzalez‐Duarte, Alejandra, Gil, Ramon, Gudesblatt, Mark , Khemani, Pravin , Kumar, Rajeev , Lamotte, Guillaume, Liu, Andy , Miglis, Mitchell G. , Reynolds, Adam , Sahagian, Gregory A., Saint‐Hilaire, Marie‐Helene, Schwartzbard, Julie, Yerstein, Oleg , Freeman, Roy, Claassen, Daniel O. , Liu, Andy , Claassen, Daniel , Miglis, Mitchell G , Singer, Wolfgang , Soileau, Michael J , Vernino, Steven , Freeman, Roy L. , Kaufmann, Horacio , Gibbons, Christopher , Adler, Charles H. , Evidente, Virgilio Gerald H. , Galasko, Douglas , González-Duarte, Alejandra , Isaacson, Stuart , Lamotte, Guillaume , McFarland, Nikolaus R. , Reynolds, Adam, Sahagian, Gregory , Vernino, Steven , Millar Vernetti, Patricio

Mayo Clinic

Annals of Clinical and Translational Neurology | December 26, 2025 | Volume: 13 | Issue: 5 | Pages: 1041-1051

10.1002/acn3.70291 | PMID 41449577 Get It

ABSTRACT Objective To determine the test performance of cutaneous phosphorylated alpha‐synuclein (P‐SYN) in dementia with Lewy bodies (DLB), individuals with reduced Montreal Cognitive Assessment (MoCA) and healthy controls. Methods This is the first subgroup analysis of the Synuclein‐One study, a prospective, blinded study evaluating P‐SYN detection from skin biopsies in 218 subjects with a referral diagnosis of control ( N = 151) and DLB ( N = 67). All subjects completed detailed examinations, questionnaires, and had skin biopsies for detection of P‐SYN. DLB patients were included if meeting the 4th DLB consensus probable criteria. Control subjects, aged 40–99, had no history, examination findings, or symptoms suggestive of a synucleinopathy or neurodegenerative disease. An expert review panel, blinded to pathological data, determined the final diagnosis. Controls with reduced MoCA (MoCA < 26, N = 26) at screening were analyzed separately. Results After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA. The proportions of subjects with cutaneous P‐SYN detected by skin biopsy were 96.0% (48 of 50) of the DLB group, 31% (8 of 26) of the controls with reduced MoCA, and 3.3% (4 of 120) of the controls with normal MoCA. Interpretation In this prospective, blinded, cross‐sectional study, a high proportion of subjects meeting clinical consensus criteria for DLB had P‐SYN detected in skin biopsies. Almost 1/3 of subjects with reduced MoCA testing also had P‐SYN detected. These results support a role for skin biopsy detection of P‐SYN in patients with DLB. Trial Registration NCT04700722
Epigenetics in chronic rhinosinusitis
Kumar, Bharat , Lal, Devyani, Brar, Tripti

Mayo Clinic

Current Opinion in Otolaryngology & Head & Neck Surgery | December 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/moo.0000000000001101 | PMID 41442742 Get It

Purpose of review Increasing evidence suggests that epigenetic regulation plays a central role in chronic rhinosinusitis pathogenesis, heterogeneity, and treatment response. This review summarizes current knowledge of epigenetics in CRS pathogenesis, their role in endotype differentiation, and potential as diagnostic and therapeutic targets. Recent findings Distinct epigenetic signatures have been identified across CRS subtypes. Hypermethylation of TSLP and differential regulation of FZD5, IL8, and EMT-related genes distinguish eosinophilic CRSwNP from other phenotypes. Specific microRNAs (miR-941, miR-21, miR-125b, miR-155) correlate with disease severity, tissue eosinophilia, and corticosteroid responsiveness, highlighting their utility as noninvasive biomarkers. Experimental data suggest that targeting DNMTs or HDACs may reverse pathogenic remodeling. Emerging therapeutic approaches – such as biologics modulating epigenetically controlled cytokines (e.g. tezepelumab) and engineered extracellular vesicle-based miRNA delivery – illustrate translational promise. Summary Epigenetic mechanisms critically influence CRS pathogenesis and clinical variability. Their modulation offers novel opportunities for biomarker discovery, disease stratification, and personalized therapy. Future research should focus on standardizing epigenetic profiling methodologies, validating candidate biomarkers in diverse populations, and integrating multiomics and single-cell approaches to uncover cell-specific regulatory networks. These advances may enable precision medicine in CRS, bridging the gap between molecular mechanisms and targeted clinical management.